# HUS Comprehensive Cancer Center, Helsinki University Hospital

Source: https://onco.cc/institutions/helsinki-hus/  
OnCo record `helsinki-hus` (Institution). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Finland's largest cancer centre and an OECI-accredited comprehensive cancer centre, known for hereditary cancer genetics and functional precision medicine in leukaemia.

## Summary

The HUS Comprehensive Cancer Center is the tertiary cancer centre for the Helsinki region and a national referral centre, accredited by the OECI. University of Helsinki research includes Lauri Aaltonen's discoveries in hereditary colorectal cancer and uterine fibroid genetics, the Hematology Research Unit Helsinki (Kimmo Porkka, Satu Mustjoki) on leukaemia immunology, Sirpa Leppä's lymphoma trials for the Nordic Lymphoma Group, and the Institute for Molecular Medicine Finland, where Olli Kallioniemi's group developed drug sensitivity and resistance testing of patient leukaemia cells. The centre coordinates the national FICAN network and benefits from Finland's cancer registry and biobank infrastructure.

## Fields

- Kind: Institution
- Last checked: 2026-09-09
- Also known as: HUS Syöpäkeskus; Helsinki University Hospital Comprehensive Cancer Center; HUCH Cancer Center
- City: Helsinki, FI
- Type: cancer-center
- Website: https://www.hus.fi/

## Sources

- HUS Comprehensive Cancer Center (page moved; nearest live section): https://www.hus.fi/
- FIMM: https://www.helsinki.fi/en/hilife-helsinki-institute-life-science/units/fimm

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/), [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/), [Functional (ex vivo) drug testing](https://onco.cc/technologies/functional-drug-testing/), [Germline (hereditary) testing](https://onco.cc/technologies/germline-testing/), [Whole-exome & whole-genome sequencing](https://onco.cc/technologies/wes-wgs/)
- institutions: [Finnish Cancer Center (FICAN)](https://onco.cc/institutions/fican/), [Karolinska University Hospital](https://onco.cc/institutions/karolinska/), [Kuopio University Hospital Cancer Center](https://onco.cc/institutions/kuopio-university-hospital/), [Organisation of European Cancer Institutes](https://onco.cc/institutions/oeci/), [Tays Cancer Centre, Tampere University Hospital](https://onco.cc/institutions/tays-cancer-centre/), [Turku University Hospital Cancer Centre](https://onco.cc/institutions/turku-university-hospital/)
- terms: [Germline vs somatic mutations](https://onco.cc/terms/germline-vs-somatic/)
- people: [Heikki Joensuu](https://onco.cc/people/heikki-joensuu/), [Johanna Mattson](https://onco.cc/people/johanna-mattson/)
- bottlenecks: [Inherited risk is mostly unidentified](https://onco.cc/bottlenecks/b-hereditary-risk/)
- key papers: [Identification of Lynch syndrome among patients with colorectal cancer](https://onco.cc/key-papers/paper-moreira-lynch-syndrome-identification-jama-2012/)

---
JSON: https://onco.cc/api/v1/entities/helsinki-hus.json